How should we address the inevitable harms from non‐negligent variant reclassification in predictive genetic testing?
Authors:
Open Access
- 19 October 2022
- journal article
- research article
- Published by Wiley in Journal of Genetic Counseling
- Vol. 32 (1) , 18-30
Abstract
The process of interpreting genetic variants, in which experts use all available evidence to determine whether an identified variant is associated with a current or future disease, is both scientific and nevertheless subjective. In this paper, we summarize the existing evidence that any given variant could be reclassified and that such a reclassification could lead to harm. Furthermore, the racial gap in genetic databases could lead to a higher likelihood of harm for non‐white patients. We also review recent legal analyses indicating it is unlikely that an individual who sues for restitution would be successful, especially in the absence of evidence of lab negligence. We then propose a compensation program for medical genetic tests to ensure that individuals who experience demonstrable harm due to a variant reclassification can be made whole financially. We conclude by discussing outstanding questions that must be answered for such a program to be feasible.Keywords
This publication has 23 references indexed in Scilit:
- Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer riskGenetics in Medicine, 2018
- Diversity and inclusion in genomic research: why the uneven progress?Journal of Community Genetics, 2017
- Physicians’ Duty to Recontact and Update Genetic AdvicePersonalized Medicine, 2017
- Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVarGenetics in Medicine, 2017
- Genomics is failing on diversityNature, 2016
- Genetic Misdiagnoses and the Potential for Health DisparitiesNew England Journal of Medicine, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Can I be sued for that? Liability risk and the disclosure of clinically significant genetic research findingsGenome Research, 2014
- A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South AsiaNature Genetics, 2009
- Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathyJournal of Molecular and Cellular Cardiology, 2003